Related Experiment Video
Updated: Apr 17, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Neoadjuvant Chemotherapy (NC) Response in Patients with Breast Cancer According to Immunohistochemical Intrinsic
Eva Ruvalcaba Limón1, Lilian Elizabeth Barreda Zelaya1, Nathaly García Orozco2
1Departamento de Oncología Mamaria Quirúrgica, Instituto de Enfermedades de la Mama (IEM), Fundación del Cáncer de Mama, A.C. (FUCAM), México, D.F.
Introduction:
Breast cancer is heterogeneous, with different responses to NC even within similar histology and stages.
Objective:
To evaluate clinical/pathological response to NC according to different tumor subtypes in Mexican breast cancer patients.
Patients And Methods:
Retrospective study of patients with breast cancer stages II-III, and complete immunohistochemistry (IHC), such as hormonal receptors HER2 and Ki67, treated with NC and surgery. Descriptive and comparative analyses between different intrinsic subtypes were performed.
Results:
A total of 117 patients were included with 48.6 ± 10.6 years of age, stage II (24%), and III (76%). We identified 20 (17.1%) cases of luminal A, 37 (31.6%) luminal B HER2-, 13 (11.1%) luminal B HER2+, 12 (10.3%) HER2+, and 35 (29.9%) triple negative. Clinical complete response (tumor and lymph nodes) in luminal A was 10%, in luminal B HER2- 10.8%, luminal B HER2+ 15.4%, HER2+ 25%, and in triple negative 14.3%. Conservative surgeries were done in 9 (7.7%) patients. There is a weak positive association between Ki67 expression and tumor clinical response. Pathological complete response occurred in 8 (6.83%) cases, being more frequent in luminal B HER2+ patients (23%).
Conclusions:
Pathological complete responses were more often in luminal B HER2+ cases.
